Uracil Mustard (Uramustine)

Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.

Also Known As:

Uramustine; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; Mustard, Uracil; 2,4(1H,3H)-Pyrimidinedione, 5-(bis(2-chloroethyl)amino)-

Networked: 22 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kohorn, Ernest I: 1 article (08/2013)

Related Diseases

1.	Thrombocytosis (Thrombocythemia) 09/26/1980 - "Uracil mustard is an effective drug for the control of thrombocytosis." 09/26/1980 - "Uracil mustard in the treatment of thrombocytosis." 03/01/1970 - "Uracil mustard in the treatment of thrombocythemia." 09/26/1980 - "Uracil mustard was used for the treatment of thrombocytosis in 14 patients, eight who had polycythemia vera and six who had essential thrombocytosis. " 05/01/1988 - "The alkylating agent, uracil mustard (UM), which is an effective agent for controlling thrombocytosis, has not been reported to be leukemogenic. "
2.	Lymphoma (Lymphomas) 02/01/1962 - "Effect of uracil mustard in malignant lymphoma and chronic lymphatic leukemia." 04/01/1961 - "Effect of uracil mustard in chronic lymphatic leukemia and malignant lymphoma." 04/20/1961 - "Uracil mustard, a new alkylating agent for oral administration in the management of patients with leukemia and lymphoma." 05/15/1999 - "Uracil mustard is an unmarketed, inexpensive oral alkylating agent that has been effective in the treatment of patients with lymphoma, chronic lymphatic leukemia, and thrombocythemia. "
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/01/1962 - "Effect of uracil mustard in malignant lymphoma and chronic lymphatic leukemia." 04/01/1961 - "Effect of uracil mustard in chronic lymphatic leukemia and malignant lymphoma." 05/15/1999 - "Uracil mustard is an unmarketed, inexpensive oral alkylating agent that has been effective in the treatment of patients with lymphoma, chronic lymphatic leukemia, and thrombocythemia. "
4.	Neoplasms (Cancer) 03/19/1965 - "Uracil mustard, injected intraperitoneally, increased the incidence and average number of pulmonary tumors in A/J mice. " 03/19/1965 - "URACIL MUSTARD: A POTENT INDUCER OF LUNG TUMORS IN MICE." 04/01/1968 - "Uracil mustard (NSC-34462) therapy in uncommon malignant neoplasms in children." 08/01/1972 - "Single, combined and sequential use of uracil mustard and prednisone in the treatment of lymphoreticular tumors." 01/01/1964 - "EFFECTS OF URACIL MUSTARD ON IN VIVO INCORPORATION OF PRECURSORS INTO NUCLEIC ACIDS OF THE WALKER TUMOR."
5.	Leukemia 05/01/1962 - "Uracil mustard therapy in acute leukemia in children." 05/01/1988 - "Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard." 05/01/1962 - "Management of human leukemias and Hodgkin's disease with Dopan (uracil mustard)." 04/20/1961 - "Uracil mustard, a new alkylating agent for oral administration in the management of patients with leukemia and lymphoma."

Related Drugs and Biologics

1.	Alkylating Agents
2.	Thiosemicarbazones
3.	Thioguanine (Tioguanine)
4.	Prednisone (Sone)
5.	Nucleic Acids
6.	Nuclear Proteins (Protein, Nuclear)
7.	Fluorouracil (Carac)
8.	Diethylnitrosamine (N-Nitrosodiethylamine)
9.	Cyclophosphamide (Cytoxan)
10.	Carcinogens

Related Therapies and Procedures

1.	Therapeutics
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Oral Administration